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Abstract  
In multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) 
autoaggressive CD4+ T cells cross the blood-brain barrier (BBB) and cause neuroinflammation. 
Therapeutic targeting of CD4+T-cell trafficking into the CNS by blocking α4-integrins has proven 
beneficial for the treatment of MS but comes with associated risks, probably due to blocking CD8+ T 
cell mediated CNS immune surveillance.  Our recent observations show that CD8+ T cells also rely on 
α4β1-integrins to cross the BBB. Besides vascular cell adhesion molecule-1 (VCAM-1), we identified 
junctional adhesion molecule -B (JAM-B) as a novel vascular α4β1-integrin ligand involved in CD8+ T-
cell migration across the BBB. This prompted us to investigate, if JAM-B also mediates CD4+ T-cell 
migration across the BBB.  We first ensured that encephalitogenic T cells can bind to JAM-B in vitro 
and next compared EAE pathogenesis in JAM-B-/- C57BL/6J mice and their wild-type littermates. 
Following immunization with MOGaa35-55 peptide, JAM-B-/-
 
mice developed ameliorated EAE compared 
to their wild-type littermates. At the same time, we isolated higher numbers of CD45+ infiltrating 
immune cells from the CNS of JAM-B-/-
 
C57BL/6J mice suffering from EAE. Immunofluorescence 
staining revealed that the majority of CD45+ inflammatory cells accumulated in the leptomeningeal and 
perivascular spaces of the CNS behind the BBB but do not gain access to the CNS parenchyma. 
Trapping of CNS inflammatory cells was not due to increased inflammatory cell proliferation. Neither a 
loss of BBB integrity or BBB polarity potentially affecting local chemokine gradients nor a lack of focal 
gelatinase activation required for CNS parenchymal immune cell entry across the glia limitans could 
be detected in JAM-B-/- mice. Lack of a role for JAM-B in the effector phase of EAE was supported by 
the observation that we did not detect any role for JAM-B in EAE pathogenesis, when EAE was 
elicited by in vitro activated MOG aa35-55-specific CD4+effector T cells.  On the other hand, we also 
failed to demonstrate any role of JAM-B in in vivo priming, proliferation or polarization of MOG aa35-55-
specific CD4+ T cells in peripheral immune organs.  Finally, our study excludes expression of and thus 
a role for JAM-B on peripheral and CNS infiltrating myeloid cells. Taken together, although endothelial 
JAM-B is not required for immune cell trafficking across the BBB in EAE, in its absence accumulation 
of inflammatory cells mainly in CNS leptomeningeal spaces leads to amelioration of EAE.  
Highlights 
• CNS expression of the tight junction molecule JAM-B is restricted to endothelial cells but not 
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correlated to barrier characteristics of CNS endothelial cells 
• JAM-B does not play an essential role in establishing BBB integrity at the level of tight 
junctions 
• Absence of JAM-B does not inhibit immune cell migration across the BBB but ameliorates 
clinical signs of actively induced EAE  
• JAM-B is not expressed on mouse myeloid cells  
• Ameliorated EAE in JAM-B-/- C57BL/6 mice seems to be due to the trapping of immune cells 
mainly in leptomeningeal and to a lower degree in perivascular CNS spaces 
 
Keywords: Junctional adhesion molecules, experimental autoimmune encephalomyelitis, glia 
limitans, gelatinases, tight junctions, blood-brain barrier  
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1 Introduction 
The central nervous system (CNS) coordinates all body and mental functions in vertebrates and 
proper communication of its neurons requires CNS homeostasis. Protection from the changing milieu 
of the blood stream is provided by the endothelial blood-brain barrier (BBB). The BBB is established 
by biochemically and ultrastructurally unique microvascular endothelium that prohibits free diffusion of 
molecules into the CNS by its low pinocytotic activity and the complex and continuous tight junctions 
sealing the inter-endothelial space.  At the same time, the BBB ensures transport of nutrients into and 
toxic metabolites out of the CNS by expression of carriers and transporters and efflux pumps (Abbott 
et al., 2010; Campos-Bedolla et al., 2014; Engelhardt and Coisne, 2011).  In its barrier function, the 
BBB also controls the migration of immune cells across the BBB, which occurs at the level of post-
capillary venules. The CNS is an immune privileged organ, in which foreign antigens fail to elicit a 
rapid adaptive immune response (Engelhardt et al., 2017). During immune surveillance, low numbers 
of activated T cells are able to cross the endothelial BBB and the endothelial basement membrane to 
reach the cerebrospinal fluid (CSF) drained subarachnoid and perivascular spaces and the ventricles 
(Kivisakk et al., 2003). These T cells are separated from the CNS parenchyma proper by the glia 
limitans, which is composed of the parenchymal basement membrane and astrocyte endfeet and 
surrounds the entire CNS parenchyma (Engelhardt and Sorokin, 2009). These morphological features 
allow for CNS immune surveillance in CSF filled spaces without endangering CNS homeostasis 
(Engelhardt and Coisne, 2011; Engelhardt and Ransohoff, 2012).  
During neurological disorders, such as multiple sclerosis (MS) and its animal model experimental 
autoimmune encephalomyelitis (EAE), a large number of circulating immune cells cross the CNS 
barriers and cause neuroinflammation after entering the CNS parenchyma, as well as demyelination 
and focal loss of BBB integrity, which all contribute to EAE pathogenesis. BBB breakdown is an early 
hallmark of MS as indicated by the leakage of gadolinium contrast agent across the BBB visualized by 
magnetic resonance imaging (MRI) (Tommasin et al., 2017).  
Immune cell trafficking into the CNS in autoimmune neuroinflammation is distinct from that in 
peripheral organs as it requires the immune cells to first breach the endothelial BBB and subsequently 
the glia limitans in order to reach the CNS parenchyma.  T-cell migration across the BBB is a multi-
step process initiated by α4β1-integrin-mediated capture and adhesion strengthening of the T cells via 
binding to vascular cell adhesion molecule (VCAM)-1 on the BBB (Coisne et al., 2009; Vajkoczy et al., 
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2001). Subsequently the T cells crawl on endothelial ICAM-1 and ICAM-2 to paracellular or 
transcellular sites permissive for diapedesis (Abadier et al., 2015; Steiner et al., 2010). The precise 
mechanisms involved in T-cell diapedesis across the BBB remain to be explored. Once they have 
crossed the BBB, T cells need to encounter their cognate antigen on macrophages or dendritic cells 
strategically localized in the leptomeningeal or perivascular spaces to be stimulated to produce pro-
inflammatory mediators including TNF-α, IFN-γ, and IL-17 that trigger further mechanisms required for 
subsequent CNS tissue invasion (Bartholomaus et al., 2009). Focal activation of matrix-
metalloproteinases (MMP) -2 and MMP-9 alter chemokine activation and induce degradation of 
extracellular matrix receptors on astrocyte end-feed, which is prerequisite for inflammatory cell 
migration across the glia limitans and onset of clinical EAE (Agrawal et al., 2006; Song et al., 2015).  
There is in vitro and in vivo evidence demonstrating that activated CD4+ T cells can cross the BBB via 
a transcellular route that involves pore formation through the endothelial cell body or via a paracellular 
route, which requires displacement of the junctional complexes between adjacent endothelial cells 
(Abadier et al., 2015; Lutz et al., 2017; Winger et al., 2014). The complex BBB TJs are composed of 
the transmembrane proteins occludin and members of the claudin family (Furuse et al., 1993; Nitta et 
al., 2003; Tietz and Engelhardt, 2015). In addition, the classical junctional adhesion molecules (JAM) -
A, JAM-B, and JAM-C are localized in the BBB TJs (Arrate et al., 2001; Aurrand-Lions et al., 2001a; 
Aurrand-Lions et al., 2001b; Padden et al., 2007; Tietz and Engelhardt, 2015; Vorbrodt and 
Dobrogowska, 2004; Wyss et al., 2012). These classical JAMs belong to the immunoglobulin (Ig) 
superfamily and comprise a subfamily of three more closely related cortical thymocyte marker for 
Xenopus (CTX) proteins. Classical JAMs are type I transmembrane proteins composed of two 
extracellular Ig domains and a short cytoplasmic domain containing a PDZ-binding motive (Garrido-
Urbani et al., 2014; Martin-Padura et al., 1998). JAMs engage in homophilic and heterophilic 
interactions amongst their family members. Homophilic interaction of JAM-A regulates cell polarity by 
intracellular association with the cell-polarity PAR (partitioning-defective)-3/atypical protein kinase C 
(aPKC)/PAR-6 complex (Ebnet et al., 2001). Interestingly, loss of vascular JAM-A immunostaining 
correlates with BBB leakiness in human brain tissue from MS patients (Padden et al., 2007). 
Homophilic JAM-C interactions might contribute to brain barriers junction integrity as loss of function 
mutations of JAM-C lead to hydrocephalus in mice and man (Mochida et al., 2010; Wyss et al., 2012).  
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Besides their potential role in tight junction integrity, JAMs contribute to leukocyte trafficking across 
vascular walls during inflammation by interacting with leukocyte integrins. While endothelial JAM-A 
binds to αLβ2-integrin (LFA-1) on T cells and contributes to their migration across endothelial 
monolayers in vitro (Ostermann et al., 2002), vascular JAM-C can interact with αMβ2-integrin (Mac-1) 
on myeloid cells and mediate their diapedesis in vitro and in vivo (Chavakis et al., 2004).  JAM-B is the 
least investigated member of the classical JAMs with its expression restricted to vascular endothelial 
cells and bone marrow stromal cells (Arcangeli et al., 2011; Aurrand-Lions et al., 2001b; Martin-
Blondel et al., 2015; Palmeri et al., 2000). When interacting with JAM-C, JAM-B was shown to regulate 
the migration of immune cells across the endothelium (Arrate et al., 2001). In addition, JAM-B can 
engage α4β1-integrin on human T cells following prior interaction of JAM-B with JAM-C co-expressed 
on these T cells (Cunningham et al., 2002). Furthermore JAM-B was shown to mediate α4β1-integrin 
dependent T-cell rolling and adhesion to endothelial cells in vitro independent of JAM-C  (Ludwig et 
al., 2009).  
α4β1-integrins play a dominant role in the migration of T cells across the BBB, which is a critical step 
in the pathogenesis of autoimmune CNS inflammation such as MS or its animal model EAE 
(Engelhardt and Kappos, 2008). Therapeutic targeting of α4-integrin mediated T-cell migration across 
the BBB has proven very efficient in the treatment of MS, does however have the risk of progressive 
multifocal leukoencephalopathy (PML) (Engelhardt et al., 2005), an opportunistic infection of 
oligodendrocytes by the JC virus. It has been speculated that this is due to interfering with CD8+ T cell 
mediated CNS immune surveillance. In fact, we could recently show that α4β1-integrins are essential 
for CD8+ T-cell entry into the CNS in a CD8+ T-cell mediated mouse model of autoimmune 
neuroinflammation (Martin-Blondel et al., 2015). Interestingly, although blocking of its vascular ligand 
VCAM-1 partially reduced CD8+ T-cell infiltration into the CNS it failed to reduce clinical disease. 
Rather, antibody mediated inhibition of JAM-B reduced the number of CNS-infiltrating CD8+ T cells 
and ameliorated clinical disease.  
This prompted us to explore, if vascular JAM-B is also involved in mediating CD4+ T cell trafficking 
across the BBB in neuroinflammation. To this end, we studied EAE pathogenesis as a CD4+ T-cell 
driven autoimmune neuroinflammatory model in C57BL/6J mice with a constitutive lack of JAM-B.  
 
2 Material and Methods 
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2.1 Mice 
Production of JAM-B deficient mice has been described before (Arcangeli et al., 2011). JAM-B-/- mice 
used in the present study were back-crossed for more than 12 generations on the C57BL/6J 
background. Mice were housed in individual ventilated cages under specific pathogen free conditions. 
All animal procedures were performed in accordance with the Swiss legislation on the protection of 
animals and were approved by the Veterinary Office of the Canton of Bern (permission numbers: BE 
42/14, BE 72/15, and BE 31/17). 
 
2.2 Experimental autoimmune encephalomyelitis 
Active EAE was induced in 8-12 weeks old female JAM-B-/- C57BL/6J and wild-type littermates using 
the MOGaa35-55-peptide as described before (Coisne et al., 2009). Pertussis toxin was applied 
intraperitoneally either at the days 0 (day of immunization) and 2 or alternatively at days 1 and 3 post 
immunization.  Adoptive transfer EAE was induced by injection of purified in vitro stimulated polyclonal 
CD4+ T cells from either C57BL/6J mice or JAM-B-/- littermates as described previously (Abadier et al., 
2015). 2.5 x 106 T cells were injected in 500 µl PBS intraperitoneally into syngeneic recipient wild-type 
or JAM-B-/- mice.  Assessment of clinical disease activity was performed twice daily as described 
before (Engelhardt et al., 2005; Tietz et al., 2016) as follows: 0, healthy; 0.5, limp tail; 1, hind leg 
paraparesis; 2, hind leg paraplegia; 3, hind leg paraplegia with incontinence.  
 
2.3 FACS analysis of CD45+ inflammatory cells isolated from the brain and spinal cord 
Inflammatory cells from the CNS were isolated as described previously (Doring et al., 2007). 
For surface staining, cells were resuspended in FACS-buffer (DPBS, 2.5 % FBS, and 0.1% NaN3) and 
distributed into wells of a 96-well U-bottom plate. After Fc-block (in house, clone 2.4G2) for 15 min on 
ice, inflammatory cells were incubated with primary antibody (supplementary table 1) mixes for 30 min 
on ice. After two washing steps samples were fixed with 1 % formaldehyde in FACS buffer. Blood and 
bone marrow samples were fixed with the BD FACSTM Lysing Solution (BD Biosciences) and 
erythrocytes were lysed in parallel. For intracellular cytokine staining, inflammatory cells were 
stimulated with 50 ng/ml phorbol myristate acetate (PMA; Alexis Biochemicals), 1 mg/ml Ionomycin 
(BioVision, Inc.) and 3.3 µl/10 ml Golgi stop (BD Biosciences) for 5 h at 37 °C in 5 ml RPMI1640 
(Gibco) supplemented with 10 % FBS, 2 % L-glutamine (Gibco), 1 % NEAA (Gibco), 1 % sodium 
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pyruvate (Gibco), 1 % PenStrep (Gibco), and 0.4 % 14.3 mM β-Mercaptoethanol (Merck). After the 
stimulation cells were collected and fixed and permeabilized for 20 min. on ice (BD Biosciences; 
Cytofix/CytopermTM). After a washing step, 50 µl of antibody master mixes diluted in Perm/WashTM 
solution (BD Biosciences) were added to the cells and incubated for 30 min. on ice. Cells were 
washed twice after the staining and resuspended in FACS buffer. 
For counting of the absolute cell numbers isolated from the CNS of mice fluorescent bead counting 
(BD TrucountTM; BD Biosciences or PKH26 Reference Microbeads; Sigma-Aldrich) was performed. 
Flow cytometry was performed using either the FACSCalibur (BD Bioscience), or the LSR-II (BD 
Bioscience) and data were analyzed with FlowJo software (FlowJo version 10).  
 
2.4 FACS analysis of inguinal lymph node lymphocytes 
Lymphocytes were isolated from PBS perfused mice at the peak of the EAE using a Wheaten 
homogenizer. Subsequently cells were filtered though a 100 µm nylon mesh and washed with wash 
buffer (DMEM supplemented with 5 % calf serum and 25 mM HEPES). After Fc-blockage (home made 
anti CD16/32; clone 2.4G2) for 15 min cells were resuspended in primary antibody solution for 30 min 
in FACS buffer. Flow cytometry analysis was performed using the Attune NxT (Thermofisher 
scientific). Data analysis was performed with FlowJo software. 
 
2.5 Analysis of in vivo cell proliferation 
Leukocyte cell proliferation was assessed using 5-ethynyl-2’-deoxyuridine (EdU). Mice suffering from 
EAE were injected with 0.4 mg EdU (Click-iTTM EdU AlexaFluorTM 488 Kit; Thermofisher scientific) i.p. 
at day 15 after EAE induction and brains and spinal cords were harvested 24 h later. CD45+ infiltrating 
immune cells were isolated as described before (Doring et al., 2007) and stained with anti-CD45-APC 
antibody. Subsequently EdU incorporation was fluorescently labelled by the click reaction following the 
manufacturers instructions. EdU AlexaFluorTM positive leukocytes were identified using the Attune NxT 
(Thermofisher scientific). Data analysis was performed with FlowJo software. 
  
2.6 FACS sorting of CD45hi and CD45inter CNS-infiltrating cells 
CNS-infiltrating cells were isolated from the brain and spinal cord as explained above. After Fc-block 
(in house, clone 2.4G2) for 15 min on ice, inflammatory cells were incubated with anti-CD45 antibody 
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for 45 min on ice and washed two times with DPBS. Cells were then incubated with 200 µl Fixable 
Viability Dye (FVD) eFluorTM 506 following the manufactures instructions (Thermo Fisher Scientific). 
Cells were washed two times with FACS-buffer and resuspended in FACS-sorting buffer (DPBS, 2 % 
FBS, 25 mM HEPES). Single FVD eFluorTM506-CD45interSSChi and single FVD eFluorTM506-CD45hi 
cells were sorted using FACS Aria (BD Bioscience) and RNA was isolated as described under 2.7. 
 
2.7 Real-time PCR 
Sample RNA was isolated following the manufacturers instruction of the High Pure RNA Isolation Kit 
(Hoffman-La Roche, Basel). Sample cDNA was synthetized from 500 ng sample RNA following the 
manufacturer’s instructions of the SuperScript® III First-Stand Synthesis System for RT-PCR 
(Invitrogen). mRNA expression was tested using TakyonTM Low Rox SYBR MasterMix dTTP Blue 
(Eurogentec). Quantitative real-time PCR was run in a volume of 20 µL per reaction: 10 µL of TakyoTM 
Low Rox SYBR MasterMix dTTP Blue, 0.4 µL of each primer (supplementary Table 2), 4.2 µL H2O 
and 0.25 ng/µl cDNA. The PCR was performed according to the manufacturer's protocol using 
MicroAmp Fast Optical 96-Well Reaction Plates (Thermo Fisher Scientific). For each PCR run, a 
negative control was used with the normal mix without the addition of the cDNA and with H2O instead. 
S16 ribosomal protein mRNA levels were used as an endogenous control. All qPCR reactions were 
performed using the Viia7 Real-Time PCR System (Thermo Fisher Scientific). Relative expression 
values were calculated according to the comparative ΔCT method (ΔCT value = average CT value of 
target gene - average CT value of endogenous reference). Each sample’s expression was assayed 
three times, in triplicate per run.  
 
2.8 Immunofluorescence staining 
Mouse tissue preparations and immunofluorescence staining was performed as described previously 
(Martin-Blondel et al., 2015). Briefly, to stain for CD45, 6 µm cryosections were fixed with acetone at 4 
°C for 20 min, followed by treatment with blocking buffer (5 % skimmed milk, 0.3 % TritonX100, 0.04 
% NaN3 in DPBS). Primary rat anti-mouse CD45 (supernatant, in house, hybridoma clone M1/9) or 
biotinylated goat anti-mouse IgG antibody (10 µg/ml; Vector Laboratories) and rabbit anti-mouse 
laminin (0.95 µg/ml; DAKO, Agilent) antibodies were incubated with the section for 1 h. For staining of 
JAM-B, 6 µm cryostat sections were ﬁxed with ice-cold methanol for 20 s, followed by treatment with 
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blocking buffer (2% BSA, 1% FCS, 1% donkey serum in DPBS). Subsequently, primary rabbit anti-
JAM-B antibody (αJB829 1:250, Beat Imhof) and rat anti-mouse PECAM-1 (MEC13.3, 20 µg/ml) was 
incubated with the sections for 1 h. Antibody incubation was performed at room temperature and in 
between and after antibody incubation, sections were washed with TBS. Streptavidin-Alexa488 (2.5 
µg/ml; Biolegend) was incubated for 1 h and second stage antibody staining was performed as 
described previously (Martin-Blondel et al., 2015) and immunofluorescent staining was analyzed using 
a Nikon Eclipse 600 fluorescence microscope and a Zeiss microscope-based 3D Histech Pannoramic 
MIDI II slide scanner.  
For detection of glucose transporter-1 (Glut-1) and P-glycoprotine (Pgp) mice were perfused under 
deep anesthesia with 10 ml PBS followed by 2 % formaldehyde (PFA; Merck) in DPBS through the left 
ventricle of the heart and dissected tissues were post-fixed in 2 % PFA over night. 100 µm coronal 
vibratom sections were cut using a MICROM HM 650V microtome equipped with a vibrating blade 
(MICROM International GmbH). Free floating sections were blocked for two hours with blocking buffer 
and primary antibodies (anti-Glut-1 10 µg/ml, Millipore; anti-Pgp 1:25 Enzo Life Science) was 
incubated overnight at 4 °C. Sections were then washed 3 times with TBS followed by a 2 hour 
incubation at room temperature with secondary antibodies AMCA-conjugated AffiniPure goat anti-
rabbit IgG (10 µg/ml; Jackson ImmunoResearch Laboratories, Inc.) and Cy3 goat anti-mouse (3 µg/ml; 
Jackson ImmunoResearch Laboratories, Inc.) and mounted on SuperFrost Plus cover slips (Thermo 
Scientific) with Aqua-Poly/Mount (Polysciences) mounting media and coverslipped. Sections were 
imaged using a Leica TCS SP8 Confocal Microscope with Leica LAS X software.  
 
2.9 In situ zymography and immunofluorescence counterstaining 
In situ zymography and immunostaining was performed according to (Agrawal et al., 2006). Brains 
from PBS-perfused mice were snap frozen and MMP activity was localized in 6 µm non-fixed brain 
cyrosections using in situ zymography. 10 μg/ml DQ-gelatinase and 20 µg/ml cold gelatine (Thermo 
Fisher Scientific; EnzCheckTM) in reaction buffer was applied CNS cryosections, in the presence or 
absence of 50 µM phenanthroline. Slides were incubated for 4 h in a humid chamber at 37°C, washed 
in ddH2O, and fixed 5 min in −20°C methanol before immunofluorescence counterstaining.  
For counterstaining of CD45 and laminin, sections were blocked with 1 % BSA in PBS for 20 min. 
Sections were incubated with primary rat anti-mouse CD45 (10 µg/ml; BD Pharmingen; clone 30F11) 
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and rabbit anti-mouse laminin (0.95 µg/ml; DAKO, Agilent) antibodies for 1 h. Sections were then 
incubated with secondary goat anti-rat Cy3 (7.5 µg/ml; Jackson ImmunoResearch Laboratories, Inc.) 
and AMCA anti-rabbit (15 µg/ml; Jackson ImmunoResearch Laboratories, Inc.) for 1 h and mounted 
with Mowiol (Sigma-Aldrich). Antibody incubation was performed at room temperature and in between 
and after antibody incubation, sections were washed with DPBS. Sections were examined using a 
Nikon Eclipse 600 fluorescence microscope. 
 
2.10 In vivo permeability assay 
To analyze the permeability of the BBB in vivo, 2 mg Albumin-fluorescein isothiocyanate conjugate 
(Sigma-Aldrich) in 100 µl 0.9 % NaCl solution (Mini-Plasco; B. Braun) were injected intravenously into 
39-49 weeks old wild-type and JAM-B-/- mice. The tracer was allowed to circulate for 30 min. 
Subsequently mice were perfused under deep anesthesia with 10 ml PBS followed by 2 % 
formaldehyde (PFA; Merck) in DPBS through the left ventricle of the heart. Dissected tissues were 
post-fixed in 2 % PFA over night. 100 µm vibratom sections were cut using a MICROM HM 650V 
microtome equipped with a vibrating blade (MICROM International GmbH). Free floating sections were 
counterstained for PECAM-1 for detection of blood vessel endothelial. Sections were blocked for two 
hours with blocking buffer (5 % skimmed milk, 0.3 % TritonX100, 0.04 % NaN3 in DPBS) primary 
antibody (10 µg/ml; PECAM-1 in house clone MEC13.3) was incubated overnight at 4 °C. Sections 
were then washed 3 times with TBS followed by a 2 hour incubation at room temperature with goat 
anti-rat (H+L) Cy3 (3 µg/ml; Jackson ImmunoResearch Laboratories, Inc.) and then mounted on 
SuperFrost Plus cover slips (Thermo Scientific) with Aqua-Poly/Mount (Polysciences) mounting 
media and coverslipped. Sections were imaged using a Leica TCS SP8 Confocal Microscope with 
Leica LAS X software.  
To analyze the permeability of the BBB during EAE in vivo, 10 mg of fluorescent tracers (10 kDa 
dextran Alexa fluor 488 (Invitrogen, Molecular Probes) and 3 kDa dextran Texas Red (Invitrogen) were 
intravenously retro-orbital injected in 100 µl 0.9 % NaCl solution (Mini-Plasco; B. Braun) into Isoflurane 
(Provet AG) anesthetised mice suffering from EAE. Traces were allowed to circulate for 15 min. 
Subsequently mice were perfused under deep anesthesia with 10 ml PBS followed by 4 % PFA 
(Merck) in DPBS through the left ventricle of the heart. Dissected tissues were embedded in Tissue-
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Tek (Sakura Finetek). 6 µm cryostat sections were analyzed using a Nikon Eclipse 600 fluorescence 
microscope. 
 
2.11 Preparation of primary 2D2 T cells 
Primary naïve 2D2 T cells were collected from the lymph nodes and the spleen of 2D2 TCR MOG 
transgenic mice obtained from V. K. Kruchoo (Boston, MA, USA) (Bettelli et al., 2003). CD4+ T cells 
were purified by CD4+ negative selection using Dynal beads (Invitrogen). CD4+ TCR tg T cells were 
adjusted to 1 x 106 cells/ml in restimulation medium (RPMI1640 supplemented with 10 % FBS, 2 % L-
glutamine, 1 % NEAA, 1 % sodium pyruvate, 1 % PenStrep, and 0.4 % 14.3 mM β-Mercaptoethanol) 
and were mixed together with bone marrow derived dendritic cells for in vitro proliferation assy. 
 
2.12 Preparation of bone marrow derived dendritic cells and macrophages 
To differentiate cells from the bone marrow, femurs and tibias were removed from wild-type mice and 
JAM-B-/- C57BL/6J mice. After cutting off the bone ends, bone marrow cells were collected by 
centrifugation at 4000 rpm for 4 min in homemade collection tubes (a 1.5 ml Eppendorf tube equipped 
with 0.5 ml Eppendorf tube without a lid containing the lower fifth of 1 ml pipette tip). To obtain 
dendritic cells, bone marrow cells were cultured in RPMI1640 supplemented with 10 % FBS, 2 % L-
glutamine, 1 % NEAA, 1 % sodium pyruvate, 1 % PenStrep, 0.4 % 14.3 mM β-Mercaptoethanol, and 
10 % Flt3-Ligand supernatant (in house, produced from SP2/0 transfectants secreting mouse 
recombinant Flt-3L (Dehlin et al., 2008)) for 7 days. For maturation of DCs 1 µg/ml lipopolysaccharide 
(LPS from Salmonella; Sigma-Aldrich) was added on day 7 overnight.  
For differentiation of macrophages, bone marrow cells were cultured in DMEM/F12 + GlutaMAX 
medium (Gibco) supplemented with 10 % FCS, 1 % PenStrep, 2 % L-glutamine, and 1 µg/ml M-CSF 
(PeproTech, Inc.) in non-cell culture treated PD10. Medium was exchanged after 3 days and 
macrophages were matured at day 7 with 100 ng/ml LPS overnight. 
 
2.13 In vitro proliferation assay 
For in vitro proliferation of primary 2D2 T cells, LPS matured bone marrow derived dendritic cells 
(BMDCs) were collected from petri dishes using 3 ml 2 mM EDTA/PBS. 1 x 104 BMDCs were added in 
100 µl RPMI1640 supplemented with 10 % FBS, 2 % L-glutamine, 1 % NEAA, 1 % sodium pyruvate, 1 
 13 
% PenStrep, and 0.4 % 14.3 mM β-mercaptoethanol into wells of a 96-well U-bottom plate. BMDCs 
were loaded with different concentrations of MOGaa35-55 peptide (1, 2, 10, 20, 100, and 200 µg/ml) or of 
0.1 µg/ml anti-CD3- and anti-CD28-antibodies (positive control) or 10 µg/ml purified peptide derivative 
of tuberculin (PPD, negative control; Statens Serum Institute) for 1 h at 37 °C. After peptide loading of 
BMDCs 100 µl of naïve 2D2 T cells (1 x 105 cells) were added to the BMDCs and cultured for three 
days. Cells were labeled with 10 µCi/ml 3H-thymidine (PerkinElmer). After 16 h cells were harvested 
on filters. Filters were dissolved in 2 ml scintillation fluid and the cpm/min was analyzed using a beta-
counter as described in (Doring et al., 2007; Engelhardt et al., 2005).  
 
2.14 In vitro binding assay 
Wells of epoxy slides (12 well slides; Thermo Fisher Scientific) were coated with recombinant proteins 
(recombinant DNER-Fc chimera, R&D 2254-DN; recombinant ICAM-1-Fc chimera, R&D 796-IC; 
recombinant VCAM-1-Fc chimera, R&D 643-VM; recombinant MAdCAM-1-Fc chimera, R&D 993-MC; 
recombinant JAM-B-Fc chimera, R&D 988-VJ; recombinant JAM-C-Fc-chimera, R&D 1213-J3-050; 
R&D systems, Inc.) as described previously (Martin-Blondel et al., 2015). To perform the binding 
assay, in vitro MOG35-55 activated 2D2 T cells were collected at 1 x 107 cells/ml in binding buffer (TBS 
+ 1 mM MnCl2). 20 µl cell suspension (2 x 105 cells/well) were added and incubated on recombinant 
proteins on the diagnostic microscopy slide for 90 min at 37 °C. Slides were washed and the number 
of adherent cells per field of view (FOV) was quantified as previously described (Martin-Blondel et al., 
2015). 
 
2.15 Immunofluorescent staining for JAM-B on cultured cells  
Cultured Madin-Darby Canine Kidney (MDCK) cells and MDCK cells transfected with murine JAM-B 
(Aurrand-Lions et al., 2001b; Lamagna et al., 2005) were fixed with ice-cold methanol for 20 sec. After 
treatment with blocking buffer (5 % skimmed milk, 0.3 % TritonX100, 0.04 % NaN3 in DPBS) rabbit 
anti-mouse JAM-B anti-serum (JAM-B784) was incubated with the cells for 30 min. Cells were washed 
twice with PBS and incubated with secondary goat anti-rabbit (H+L) Alexa488 (5 µg/ml; Invitrogen) for 
30 min. Cells were washed twice, mounted with Mowiol and JAM-B staining was analyzed using a 
Nikon Eclipse 600 fluorescence microscope. 
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2.16 Primary mouse brain microvascular endothelial cells 
Primary mouse brain microvascular endothelial cells (pMBMECs) isolated from wild-type or JAM-B-/- 
mice were isolated and cultured exactly as described before (Coisne et al., 2013; Steiner et al., 2010). 
 
2.17 immunofluorescent staining of primary mouse brain microvascular endothelial cells 
pMBMECs were fixed with 1 % formaldehyde for 10 min. After treatment with blocking buffer for 20 
min (5 % skimmed milk, 0.3 % TritonX100, 0.04 % NaN3 in DPBS) rabbit anti-ZO-1 (1.25µg/ml; 
Invitrogen) or rat anti-VCAM-1 (clone 9DB3), or rat anti-ICAM-1 (clone 25ZC7) were incubated with 
the cells for 30 min. Cells were washed twice with PBS and incubated with secondary goat anti-rabbit 
(H+L) Alexa488 (5 µg/ml; Invitrogen) or goat anti-rat (H+L) Cy3 (7.5 µg/ml; Jackson ImmunoResearch 
Laboratories, Inc.) for 30 min. Cells were washed twice, mounted with Mowiol and JAM-B staining was 
analyzed using a Nikon Eclipse 600 fluorescence microscope. 
 
2.18 in vitro transmigration assay 
The transmigration of 2D2 T cells across pMBMECs was assessed as described before (Steiner et al., 
2011).  In brief, pMBMECs were cultured on laminin and Matigel (Corning) coated 0.33 cm2 filter 
inserts (5 µm pore size; Transwell Costar, Corning) for 6 days and stimulated with 10 ng/ml TNF 
(PromoCell GmbH) and/or 20 ng/ml IL-1β (PeproTech) for 16 h. 1 x 105 in vitro activated 2D2 cells 
were allowed to transmigrate for 8 h and the percentage of migrated T cells was calculated referring to 
the inputs as 100 %. 
 
2.19 Transendothelial permeability 
The in vitro permeability assay was performed as described previously (Steiner et al., 2011) 
(Lazarevic and Engelhardt, 2016). Briefly, pMBMECs were cultured of laminin and Matigel (Corning) 
coated 0.33 cm2 filter inserts (0.4 µm pore size; Transwell Costar, Corning) for 6 days and stimulated 
with 10 ng/ml TNF (PromoCell GmbH) for 16 h. Fluorescent tracer (50 µM Lucifer yellow, 0.457 kDa; 
Sigma-Aldrich) was provided form the luminal compartment. Fluorescence from different time points 
was detected in the lower compartment using the Tecan Infinite M1000 Pro (Tecan, Group Ltd) and 
the clearance of LY (permeability coefficient) was calculated.  
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2.20 In vitro live cell imaging under physiological flow 
Dynamic interaction of in vitro activated 2D2 T cells with wild-type and JAM-B-/- pMBMECs was 
investigated by live cell imaging under flow in vitro as described before (Coisne et al., 2013; Rudolph 
et al., 2016; Steiner et al., 2010). Briefly, 1 x 106 cells/ml 2D2 T cells were allowed to accumulate on 
the flow chamber at a low shear (0.1 dyn/cm2) for 5 min. Dynamic interactions of activated 2D2 T cells 
with the pMBMECs was recorded under physiological shear flow (1.5 dyn/cm2) for 20 min (objective 
EC Plan Neoflur 20X/0.4) with phase or contrast using a monochrome charge-coupled device camera 
(AxioCam MRm Rev, Carl Zeiss). Image analysis was performed using ImageJ software (ImageJ 
software, National Institute of Health) using the manual tracking and migration tool plugins.  
 
2.21 Western blotting of JAM-B 
Isolated microvessels or cultured primary mouse brain microvascular endothelial cells from wild-type 
or JAM-B-/- mice were tested for JAM-B expression. After isolation of microvessels red blood cells 
were lysed for 2 min at room temperature using ammonium chloride Tris-HCl solution (9:1 0.83 % 
ammonium chloride in Tris-HCl pH 7.5). Freshly isolated brain vessels as well as cultured primary 
mouse brain microvascular endothelial cells were lysed in RIPA buffer (150 mM NaCl, 1 % NP-40, 0.5 
% sodium deoxycholate, 0.1 % SDS, 50 mM Tris pH 8) containing protease inhibitor (c0mpete 
Tablets; Roche). Protein concentration was measured using the Bovine Serum Albumin assay 
(Thermo ScientificTM PierceTM Protein Biology). 30 µg of protein were mixed with 2X Sample Buffer 
(437,5 µl 8M Urea, 5.25 % SDS, 50 mM Tris, 62.5 µl, and 10 µl 0.5 % BPB) and separated by 12 % 
SDS-PAGE. Proteins were transferred to a nitrocellulose membrane (Amersham Protan, GE 
Healthcare), using a Trans-Blot Turbo transfer system (BioRad Laboratories, Hercules), according to 
the manufacturer’s instructions. Membranes were blocked with 5 % BSA () in TBST (200 mM Tris, 1.5 
M NaCl, 0.1 % Tween-20) for 1 hour at room temperature and incubated with rabbit anti-mouse 
GAPDH (CellSignaling) or rabbit JAM-B784 antiserum overnight at 4 °C. The following day, the 
membranes were washed with 3 x with TBST and incubated with the secondary antibodies goat anti-
rabbit IgG (H+L) IRDyeTM 800 (1:10000, Rockland Immunochemicals), for 1 hour, room 
temperature. Proteins were detected using the Odyssey software (LI-COR Biotechnology).  
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3 Results 
3.1 JAM-B is expressed in CNS endothelial cells of C57BL/6J mice  
We have previously shown that JAM-B is expressed in brain endothelial cells of BALB/c mice (Martin-
Blondel et al., 2015). To ensure that JAM-B is also expressed in CNS endothelial cells of C57BL/6J 
mice we performed immunofluorescence staining of frozen brain and spinal cord sections from healthy 
C57BL/6J mice (Fig. 1). JAM-B was readily detected in platelet endothelial cell adhesion molecule 
(PECAM)-1 + blood vessel endothelial cells in the cortex, the cerebellum and the spinal cord. Similarly, 
in the choroid plexus that lack an endothelial blood-brain barrier (BBB) and rather establishes an 
epithelial blood-cerebrospinal fluid barrier (BCSFB), JAM-B immunostaining was restricted to PECAM-
1+ endothelial cells and absent from choroid plexus epithelial cells. Thus, JAM-B protein is expressed 
by vascular endothelial cells irrespective of their barrier characteristics but not by the epithelial cells of 
the BCSFB in the choroid plexus.  
 
3.2 JAM-B-/- C57BL/6J mice develop ameliorated EAE 
To determine if absence of JAM-B affects pathogenesis of EAE, we immunized JAM-B-/- C57BL/6J 
mice and their wild-type littermates with MOGaa35-55 peptide in CFA. In comparison to wild-type mice, 
JAM-B-/- mice developed significantly ameliorated disease signs of actively induced EAE (aEAE; Fig. 
2A) as determined by the area under the curve (AUC; Fig. 2B). JAM-B-/- mice also showed a less 
pronounced weight loss (Fig. 2C) and a lower maximal clinical EAE score (Fig. 2D). However, lack of 
JAM-B did not affect the day of disease onset (11.77 ± 0.5 in wild-type and 13 ± 0.90 in JAM-B-/- mice) 
nor the disease incidence (incidence 100 % in both, wild-type and JAM-B-/- mice).  
 
3.3 Absence of JAM-B does not affect BBB permeability in vivo  
As JAM-B localizes to tight junctions, we asked if absence of JAM-B from the BBB tight junctions 
might lead to BBB breakdown, which is a critical hallmark of EAE pathogenesis. To this end, we first 
investigated the diffusion of intravenously applied FITC-albumin and endogenous mouse 
immunoglobulins across brain vessels in aged (39-49 weeks) wild-type and JAM-B-/- mice by 
immunofluorescence staining. Mouse immunoglobulins were readily detected in the stroma of 
circumventricular organs or the choroid plexus harboring fenestrated microvessels, but not in the CNS 
parenchyma or the leptomeninges of wild-type and JAM-B-/- mice (Supplementary Fig. 1). 
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Furthermore, absence of JAM-B was not associated with diffusion of intravenously applied FITC-
albumin beyond PECAM-1+ endothelial cells into the brain and spinal cord parenchyma or 
leptomeningeal spaces (Supplementary Fig. 1; and data not shown). This underscores that absence of 
JAM-B even in aged mice does not lead to a compromised BBB. Next we asked if absence of JAM-B 
may lead to increased BBB dysfunction under neuroinflammatory conditions. We therefore 
investigated the diffusion of the intravenously applied exogenous fluorescent tracers 3 kDa and 10 
kDa Dextran across brain vessels in JAM-B-/- C57BL/6J mice and wild-type littermates at the peak of 
EAE (Fig. 3; n = 3 wild-type, n = 2 score 2 and n = 1 score 1; n = 3 JAM-B-/- mice, n = 1 score 2, n = 2 
score 1).  Diffusion of both tracers across the fenestrated vessels of the choroid plexus was readily 
detectable. Within the brain parenchyma we observed both, leaky as well as non-leaky inflammatory 
cuffs equally distributed in wild-type and JAM-B-/- mice. Thus, lack of JAM-B did not contribute to a 
further increase in BBB permeability in EAE inflicted C57BL/6J mice.  
As lack of detection of a difference in BBB integrity in JAM-B-/- compared to wild-type mice could be 
due to the upregulated expression of other tight junction proteins in the absence of JAM-B we isolated 
brain vessels from wild-type and JAM-B-/- mice and investigated expression of JAM-A, JAM-C as well 
as additional tight junction molecules e.g. claudin-5, occludin, and ZO-1 by qPCR (Supplementary Fig. 
2). We did not find any significant differences in the mRNA expression of any of these tight junction 
molecules demonstrating that absence of JAM-B does not affect expression of other BBB tight junction 
molecules in vivo.  
 
3.4 Activated CD4+ T cells can bind to recombinant JAM-B in vitro 
We have previously shown that BBB permeability is regulated independently from T-cell trafficking 
across the BBB (Abadier et al., 2015).  To explore if JAM-B could play a role in the multi-step process 
of α4β1-integrin mediated T-cell migration across the BBB, we next investigated if CD4+ MOG35-55 
reactive 2D2 T cells can engage JAM-B. To this end, we performed in vitro binding assays allowing to 
study 2D2 T cell adhesion to recombinant JAM-B in comparison to other members of the IgCAM 
superfamily under static conditions (Supplementary Fig. 3).  2D2 T cells were found to readily bind to 
ICAM-1 and to a lower degree to VCAM-1. A low level of binding of 2D2 T cells to MAdCAM-1 and 
JAM-B could also be observed. Mixing recombinant JAM-C with JAM-B potentially allowing for prior 
engagement of JAM-B with JAM-C to facilitate α4β1-integrin/JAM-B interaction (Cunningham et al., 
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2002) did not increase T-cell adhesion to JAM-B in vitro (data not shown).  Thus, activated 2D2 T cells 
can engage JAM-B, which may contribute to their migration across the BBB during EAE.  
 
3.5 Lack of JAM-B does not affect T cell transmigration across the BBB in vitro 
To assess if endothelial JAM-B contributes to the multi-step T-cell migration across the BBB we used 
primary mouse brain microvascular endothelial cells (pMBMECs) as in vitro model of the BBB.  We 
have previously shown that pMBMECs are an excellent model allowing to delineate molecular 
mechanisms involved in T cell migration across the BBB under static and flow conditions in vitro 
(Steiner et al., 2010; Steiner et al., 2011). pMBMECs have mature tight junctions and express besides 
occludin, claudin-5, claudin-12 also JAM-A, JAM-B, and, although to a lesser extend, JAM-C (Lyck et 
al., 2009).  Comparing primary mouse brain microvascular endothelial cells (pMBMECs) from wild-
type and JAM-B-/- mice we did not observe any differences in morphology, junctional integrity 
(Supplementary Figure 4A), or in the paracellular diffusion of 0.45 kDa Lucifer yellow (Supplementary 
Figure 4B) supporting that lack of JAM-B does not impair barrier characteristics of pMBMECs in vitro.  
To our surprise we failed however to detect a positive immunostaining for JAM-B on pMBMECs 
isolated from wild-type mice, although JAM-B was readily detected on JAM-B transfected Madin-Darby 
Canine Kidney (MDCK) cells (Aurrand-Lions et al., 2001b; Lamagna et al., 2005) using the same 
staining protocol (Supplementary Figure 4C). Taking into account that JAM-B protein may be 
expressed at low levels we nevertheless searched for potential differences in T-cell interaction with 
pMBMECs from wild-type and JAM-B-/- mice. We could first confirm that cytokine stimulation of 
pMBMECs with TNF-α or IL-1β induced comparable cell surface expression levels of endothelial 
ICAM-1 and VCAM-1 on pMBMECs from wild-type and JAM-B-/- mice (data not shown). Comparing 
the migration of in vitro activated encephalitogenic 2D2 T cells across cytokine- stimulated and non-
stimulated pMBMECs isolated from wild-type or JAM-B-/- mice in a static two chamber assay we found 
not differences (Supplementary Fig. 4D). To investigate the potential role of JAM-B in mediating α4β1-
integrin mediated T cell rolling or arrest we finally investigated the multi-step T-cell migration across 
wild-type and JAM-B-/- pMBMEC monolayers under physiological flow by means of in vitro live cell 
imaging as reported before (Abadier et al., 2015; Steiner et al., 2010). We did not observe any 
difference in the ability of the 2D2 T cells to arrest on wild-type and JAM-B-/- pMBMECs under 
physiological flow (Supplementary Figure 4E). Also, post-arrest T-cell behaviour on pMBMEC 
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monolayers was found comparable in the absence or presence of JAM-B (Supplementary Figure 4E). 
To finally exclude that the in vitro studies overlooked a potential role of JAM-B in mediating T-cell 
interaction with the BBB due to very low JAM-B protein expression levels in pMBMECs we compared 
JAM-B protein expression in freshly isolated brain microvessels and pMBMECs derived from wild-type 
and JAM-B-/- mice by Western blotting. While JAM-B was as expected detectable in freshly isolated 
microvessels from wild-type mice but not in microvessels from JAM-B-/- mice, we could not detect 
JAM-B in cell lysates from wild-type and JAM-B-/- pMBMECs (Supplementary Fig. 4F).  Taken 
together, these data suggest that pMBMECs do not maintain protein expression levels of JAM-B as 
observed at the BBB in vivo.  As protein expression levels in pMBMECs are below the detection level 
of immunofluorescence stainings and Western blots, in vitro studies employing pMBMECs are not 
suitable to study a role for JAM-B in BBB integrity and T cell migration across the BBB.  
 
3.6 Increased numbers of inflammatory cells accumulate in the CNS of JAM-B-/- C57BL/6J mice 
suffering from EAE 
To investigate if endothelial JAM-B contributes to immune cell entry into the CNS during EAE in vivo 
we next isolated inflammatory cells from the brains and spinal cords of JAM-B-/- C57BL/6J mice and 
wild-type littermates at the peak of the disease. Multi-colour flow cytometry analysis revealed 
comparable percentages of CD45hi CD3+CD4+ T cells and CD45hiCD3+CD8+ T cells, CD45hi B220+ B 
cells and CD45hiLy6C+Ly6G-F4/80- recently immigrated monocytes in the brains and spinal cords of 
wild-type and JAM-B-/- mice at (Fig. 4).  Similarly, the cytokine profiles of brain and spinal cord 
infiltrating CD45hi CD3+CD4+ T cells and CD45hiCD3+CD8+ T cells positive for the Th1 signature 
cytokine interferon-γ (IFN-γ), the Th17 signature cytokine interleukin -17 (IL-17) and the 
encephalitogenic cytokine GM-CSF were comparable in JAM-B-/- mice and wild-type littermates at the 
peak of the disease (Supplementary Fig. 5). At the same time, Th2-associated cytokines were not 
increased in JAM-B-/- mice. A small and comparable subset of wild-type as well as JAM-B-/- CNS 
infiltrating CD45hi CD3+CD4+ T cells and CD45hiCD3+CD8+ T cells stained positive for IL-4 
(Supplementary Figure 5), but not IL-10 (data not shown).  
To our big surprise however, we detected significantly higher numbers of CD45hi brain infiltrating 
immune cells in JAM-B-/- mice, when compared to wild-type littermates (Fig. 4D). In fact, we isolated 
almost double as many CD45hi CD3+CD4+ T cells and CD45hiCD3+CD8+ T cells, as well as B220+ B 
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cells and Ly6C+Ly6G-F4/80- recently immigrated monocytes from the brains of JAM-B-/- mice 
compared to wild-type littermates at the peak of EAE (Fig. 4D). Similarly, in the spinal cord we 
detected increased numbers of infiltrating CD45hi CD3+CD4+ T cells and CD45hiCD3+CD8+ T cells and 
B220+ B cells, but not of CD45hi Ly6C+Ly6G-F4/80- recently immigrated monocytes (Fig. 4E). Isolation 
of higher numbers of CNS inflammatory cells from JAM-B-/- C57BL/6J mice compared to wild-type 
littermates was thus in apparent contrast to the observed ameliorated disease course observed in the 
absence of JAM-B.  
 
3.7 CNS infiltrating immune cells are trapped in leptomeningeal and perivascular spaces in 
JAM-B-/- C57BL/6J mice suffering from EAE 
To explore how the presence of increased numbers of CNS inflammatory cells in JAM-B-/- C57BL/6J 
mice compared to wild-type littermates could conform with the observed ameliorated EAE severity in 
JAM-B-/- mice versus wild-type littermates, we decided to determine the precise localization of the 
CNS infiltrating CD45+ immune cells by immunofluorescence staining of brain and spinal cord 
cryosections from JAM-B-/- mice and wild-type littermates at peak of EAE. Prior studies have shown 
that clinical EAE requires immune cell entry across the glia limitans (Agrawal et al., 2006). To 
distinguish CNS parenchymal from perivascular/leptomeningeal localization of infiltrating immune cells 
we performed multi-colour immunofluorescence analysis combining the staining for CD45+ infiltrating 
cells with that for laminin+ endothelial and parenchymal basement membranes and for nuclei as a 
general tissue landmarks. Microscopic analysis of the immunofluorescence stainings confirmed the 
presence of higher numbers of CD45+ immune cells in the brains of JAM-B-/- mice when compared to 
wild-type littermates (Fig.5). Strikingly however, in brain and spinal cord sections of all JAM-B-/- mice 
the majority of CD45+ immune cells was found to be trapped in the leptomeningeal and in some JAM-
B-/- mice also in the perivascular spaces bordered by laminin-specific immunostaining (Fig. 5 and 
Supplementary Figures 6 and 7). Furthermore JAM-B-/- mice displayed massive leptomeningeal and 
perivascular accumulations of CD45+ inflammatory cells in the cerebrum and brain stem (Figure 5) 
while in EAE in wild-type mice accumulation of inflammatory infiltrates typically localizes to the 
cerebellum and the spinal cord (Fig. 5, Supplementary Figures 6 and 7). 
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3.8 Potential causes for CNS infiltrating immune cell trapping in leptomeningeal and 
perivascular spaces in JAM-B-/- C57BL/6J mice with EAE 
It is well known that besides adhesion molecules chemokines are critically involved in medating T-cell 
trafficking into the CNS during EAE.  To determine if absence of JAM-B affects expression of 
chemokine receptors or integrins required to engage inflammatory chemokines or the parenchymal 
basement membranes, respectively, we investigated cell surface expression of chemokine receptors 
including CXCR4, CCR6, and CXCR7/ACKR3 on CNS-infiltrating T cells by flow cytometry. 
Furthermore, cell surface expression of integrin chains including α4-, α6-, and αV-integrin, as well as 
β1- and β3-integrin, and α4β7-integrin was determined on CNS-infiltrating T cells by flow cytometry.  
We failed to detect any significant difference in integrin or chemokine receptor cell surface expression 
phenotypes of CNS-infiltrating T cells in wild-type and JAM-B-/- C57BL/6J mice suffering from EAE 
(data not shown).  
 
Next we hypothesized that loss of BBB polarity in JAM-B-/- mice may lead to a loss of leptomeningeal 
or perivascular chemokine gradients and thus slow down inflammatory cell entry into the CNS 
parenchyma during EAE. Upregulated expression of the scavenging receptor CXCR7/ACKR3 on the 
BBB during EAE was previously shown to mediate internalization of CXCL12 into brain endothelial 
cells lowering its concentration in the leptomeningeal and perivascular spaces and allowing 
inflammatory cells to move towards cues provided by inflammatory chemokines produced by glial cells 
(McCandless et al., 2006) (Cruz-Orengo et al., 2011). We therefore performed immunofluorescent 
stainings of CXCL12 on brain tissues from healthy wild-type and JAM-B-/- mice as well as on brain 
tissues from mice suffering from MOGaa35-55-induced EAE and adoptive transfer EAE. In accordance to 
these previous studies we detected CXCL12 immunostaining on the basolateral aspects of brain 
vessels and in the leptomeninges in healthy wild-type and JAM-B-/- mice and this immunostaining was 
reduced in wild-type and JAM-B-/- mice suffering from EAE (data not shown). However, we did not 
observe any difference in the staining patterns between wild-type and JAM-B-/- mice.   
 
We next asked if we found any evidence for an altered BBB polarity in the absence of JAM-B. To this 
end we performed double-immunofluorescent stainings for the glucose transporter-1 (Glut-1), enriched 
at the abluminal membrane of BBB endothelial cells and P-glycoprotein (Pgp), enriched at the luminal 
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membrane of BBB endothelial cells.  We indeed found vascular immunostaining for Pgp to be 
surrounded by the staining for Glut-1 in the cortex and cerebellum of wild-type and JAM-B-/- mice 
(Supplementary Fig. 8), confirming the polarized localization of these membrane transporters at the 
BBB.  We did not observe any obvious differences in the vascular localization of Glut-1 and Pgp 
between wild-type and JAM-B-/- mice suggesting that lack of JAM-B does not lead to a loss of BBB 
polarity. 
 
Finally, pronounced accumulation of CNS infiltrating immune cells in the leptomeningeal and 
perivascular spaces could be due to a locally increased proliferation. We therefore investigated 
inflammatory cell proliferation in vivo by intraperitoneally injecting 0.4 mg 5-ethynyl-2´-deoxyuridine 
(EdU) into mice during the peak of EAE and analysing the proliferation of CNS infiltrating immune cells 
24 h later by flow cytometry.  We found comparable fractions (12-16 %) of EdU+CD45hi infiltrating 
immune cells in the brains and spinal cords of wild-type and JAM-B-/- mice during the peak of EAE 
(Supplementary Fig. 9). This suggests that the increased accumulation of inflammatory cells observed 
in the leptomeningeal and perivascular spaces in JAM-B-/- mice is not due to an increased ratio of 
immune cell proliferation.  
 
Taking together all these observations, we concluded that JAM-B is not required for immune cell 
trafficking across the BBB and does not affect the trafficking phenotype of CNS infiltrating T cells. 
Also, accumulation of inflammatory cells in leptomeningeal and perivascular spaces in JAM-B-/- mice 
during EAE can not be assigned their increased local proliferation or to a loss of BBB polarity and 
increased CXCL12 concentrations eventually slowing down immune cell trafficking into the CNS 
parenchyma.  Rather, its absence seems to reduce subsequent re-activation of encephalitogenic T 
cells in the leptomeningeal and perivascular spaces as a prerequisite for their crossing the glia 
limitans.  
 
3.9 Lack of JAM-B does not affect focal CNS activation of matrix-matalloproteinases (MMPs)  
It has been shown that focal activation of the gelatinases matrix metalloproteinase (MMP)-2 and MMP-
9 in perivascular and leptomeningeal spaces is crucial for inflammatory cell penetration of the 
parenchymal basement membrane and the onset of clinical EAE (Agrawal et al., 2006; Song et al., 
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2015). To study if absence of JAM-B interferes with focal MMP-2 and MMP-9 activation in the CNS, 
we performed in situ zymography on brain sections of JAM-B-/- C57BL/6J mice and wild-type 
littermates suffering from EAE using fluorescein-conjugated gelatine.  Combining this technique with 
immunofluorescence staining for laminin and CD45 on brain sections allowed to determine the precise 
localization of gelatinase activity with respect to endothelial and parenchymal basement membranes 
and sites of CD45+ immune cell infiltrates. Microscopic inspection of the brain sections revealed 
comparable gelatinase activity around perivascular and meningeal inflammatory cuffs in brain sections 
of wild-type mice and JAM-B-/- littermates (Fig.6). This activity could be abolished by the MMP inhibitor 
phenanthroline (data not shown).  These findings indicate that mechanisms other than MMP-2/-9 
activity cause the accumulation of inflammatory cells in the perivascular and leptomeningeal spaces in 
JAM-B-/- C57BL/6J mice during EAE (Fig. 6).  
 
3.10 JAM-B-/- C57BL/6J mice do not display altered release of bone marrow myeloid cells into 
the blood stream 
As perivascular and leptomeningeal accumulation of CNS infiltrating immune cells in JAM-B-/- 
C57BL/6J mice suffering from EAE could not be assigned to the lack of any of the known molecular 
mechanisms required for immune cell exit from these compartments, we next asked if an alteration in 
the immigration of circulating immune cells across the BBB the CNS could be an alternative 
explanation for our observations.   
JAM-B-/- mice display defects in the regulation of their hematopoietic stem cell pool leading to a 2 - 4 
fold increase in the release of myeloid cells into the blood stream upon application of hematopoietic 
stem cell mobilizing agents (Arcangeli et al., 2014; Arcangeli et al., 2011).   
We therefore asked if absence of JAM-B in C57BL/6J mice also influences mobilization of myeloid 
cells from the bone marrow into the circulation upon immunization with CFA. To this end JAM-B-/- mice 
and wild-type littermates were immunized with CFA and the cellular composition of their blood was 
analyzed at days 2, 4 and 10 after CFA immunization by flow cytometry and using a VetABCTM 
hematology analyzer. We first quantified the absolute numbers of circulating white blood cells in JAM-
B-/- mice compared to wild-type littermates in response to the CFA stimulus, employing the VetABCTM 
hematology analyzer. On days 2 and 4 after CFA injection we counted on average 1 x 104/µm3 white 
blood cells in the blood of both, wild-type and JAM-B-/- mice. This number increased to 2 x 104/µm3 
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white blood cells on day 10 after CFA challenge in both, wild-type and and JAM-B-/- mice (Fig. 7). 
Subsequent flow cytometry analysis for circulating CD45-CD117+ hematopoietic precursor cells, 
CD45+Ly6ChiLy6G-CD11b+CD115+ myeloid cells and CD45+Ly6CloLy6G+CD11b+CD115- granulocytes 
confirmed an increased number of these immune cell subsets in the blood stream from day 4 post 
immunization, yet, again we did not observe any differences in wild-type and JAM-B-/- C57BL/6J mice 
(Supplementary Fig. 10 and data not shown).  
Amongst white blood cells, lymphocytes increased form 0.5 x 104/µm3 at days 2 and 4 after the CFA 
challenge to 0.8 x 104/µm3 at day 10 and monocytes increased from 0.05 x 104/µm3 at days 2 and 4 to 
0.15 x 104/µm3 at day 10 in both, wild-type and JAM-B-/- mice (Fig. 7). Granulocytes increased the 
most from 0.25 x 104/µm3 at days 2 and 4 after the CFA challenge to 1 x 104/µm3 at day 10 (Fig. 7). 
These data underscore the mobilization of immune cells from the bone marrow into the blood stream 
upon immunization with CFA, however, they do not support a role of JAM-B in this increased release 
of immune cells or precursors from the bone marrow into the blood stream after CFA immunization.  
 
3.11 Absence of JAM-B does not ameliorate adoptive transfer EAE 
JAM-B is expressed on vascular endothelial cells including those of the high endothelial venules 
(HEVs) in lymph nodes (Pfeiffer et al., 2008) and may therefore contribute to the homing of 
lymphocytes and thus eventually to the in vivo priming of encephalitogenic T cells upon induction of 
active EAE by subcutaneous immunization with MOGaa35-55 peptide in CFA.  We therefore decided to 
further study the role of JAM-B in EAE pathogenesis by employing the passive transfer EAE model, in 
which freshly in vitro MOGaa35-55 activated CD4+ effector T cells are transferred into syngeneic 
recipients.  To this end, lymphocytes and splenocytes were harvested from JAM-B-/- C57BL/6J mice 
and wild-type littermates at day 10 after immunization with MOGaa35-55/CFA and restimulated in vitro 
with MOGaa35-55. The cytokine profile for MOGaa35-55 activated T cells derived from wild-type and JAM-
B-/- mice was found to be indistinguishable by flow cytometry (data not shown). EAE was then induced 
in wild-type and JAM-B-/- mice by transfer of 2.5 x 106 purified freshly activated CD4+ T cells from wild-
type or JAM-B-/- mice (Fig. 8). Interestingly, we did not observe any significant differences in the 
development of clinical EAE between wild-type and JAM-B-/- recipients irrespective of induction of EAE 
by MOGaa35-55 specific CD4+ T cells obtained from wild-type or JAM-B-/- mice (Fig. 8). Also, unlike in 
actively induced EAE we did not observe any differences in the size of the leptomeningeal or 
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perivascular inflammatory cuffs in the brains of wild-type or JAM-B-/- recipients suffering from EAE 
upon transfer of encephalitogenic T cells derived from either wild-type nor in JAM-B-/- mice 
(Supplementary Figure 11). These observations suggest that JAM-B is not required for the reactivation 
of encephalitogenic effector T cells in the leptomeningeal or perivascular spaces. As amelioration of 
EAE in the absence of JAM-B is thus solely observed upon disease induction immunization with 
MOGaa35-55 in CFA, JAM-B may rather play a role in peripheral in vivo priming of encephalitogenic T 
cells outside of the CNS. 
 
3.12 Lack of JAM-B does not impair MOGaa35-55 specific CD4+ T cell activation and proliferation 
To investigate a potential role for JAM-B in priming of encephalitogenic T cells in vivo, we next 
addressed if JAM-B plays a role in in vivo T cell activation and proliferation or polarization after 
immunization with MOGaa35-55 in CFA and prior to manifestation of clinical EAE.   
In light of our previous observations that JAM-B is expressed in vascular endothelial cells of lymph 
nodes (Pfeiffer et al., 2008) we first searched for potential differences in lymph node architecture of 
wild-type and JAM-B-/- C57BL/6J mice suffering from EAE. To this end, we performed 
immunofluorescent staining for Lyve-1+ lymphatic vessels, VE-cadherin+ endothelial cells, PNAd+ high 
endothelial venules and laminin+ basement membranes (Supplementary Fig. 12). We did not observe 
any significant differences in the architecture of the lymph nodes between JAM-B-/- mice and wild-type 
littermates thus excluding altered lymph node structure as a potential cause of differential 
encephalitogenic T-cell priming in wild-type versus JAM-B-/- C57BL/6J mice.  
Next we investigated if absence of JAM-B affects the composition of antigen presenting cells (APCs) 
in the draining lymph nodes in mice suffering from EAE. To this end we performed flow cytometric 
analysis of immune cell suspensions of inguinal lymph nodes of mice suffering from EAE. We found 
comparable subsets of B220+ as well as MHC-class II+ APCs and F4/80+ macrophages within the 
CD45+ immune cells of wild-type and JAM-B-/- mice (Supplementary Fig. 13). Similarly, analysis of the 
myeloid subsets present in those lymph nodes showed comparable fractions of 
CD45+CD11b+Ly6C+CD11c+ dendritic cells, as well as comparable low fractions of 
CD45+CD11b+Ly6C+Ly6G+ neutrophils to be present in the inguinal lymph nodes of wild-type and 
JAM-B-/- mice (Supplementary Fig. 13).  
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To determine if absence of JAM-B has a direct influence on the number of or the cytokine profile of T 
cells in draining lymph nodes after immunization with MOGaa35-55 in CFA, we next harvested the 
draining inguinal and axillary lymph nodes at days 6, 8 and 10 after immunization of JAM-B-/- 
C57BL/6J mice and wild-type littermates. Performing flow cytometry we did not reveal any significant 
differences in the percentage of CD4 and CD8 T cells within the CD45+ immune cell subsets isolated 
from the different lymph nodes at the investigated days after immunization between JAM-B-/- mice and 
wild-type littermates (data not shown and Supplementary Figure 14). Similarly, the cytokine profiles 
(IFN-γ, IL-17, GM-CSF) of CD4+ and CD8+ T cells from the different lymph nodes did not show any 
significant differences between JAM-B-/- mice and wild-type littermates at the investigated time points 
after immunization (data not shown and Supplementary Figure 14). Thus absence of JAM-B does not 
affect T cell priming and polarization.  
To study if absence of JAM-B influences T-cell proliferation in response to the MOGaa35-55 peptide, we 
next prepared bone marrow derived dendritic cells (BMDCs) from wild-type and JAM-B-/- C57BL/6J 
mice and matured them by overnight incubation with LPS. BMDCs derived from either wild-type or 
JAM-B-/- mice did not show any differences in the expression of MHC-II, CD80 and CD86 
(Supplementary Figure 15). BMDCs from wild-type and JAM-B-/- mice were then pulsed with MOGaa35-
55 and cultured together with naïve CD4+ 2D2 T cells for four days and antigen-specific T-cell 
proliferation was measured during the last 16 hours of co-culture by incorporation of H3-thymidine (Fig. 
9A).   BMDCs from wild-type and JAM-B-/- mice comparably induced MOGaa35-55 -specific proliferation 
of 2D2 T cells in a dose dependent manner (Fig. 9B).   
Taken together these experiments failed to show any role of JAM-B in peripheral T cell priming, 
polarization and proliferation in vivo following immunization with MOGaa35-55 in CFA.  
 
3.13 JAM-B is not expressed by brain infiltrating immune cells nor by bone marrow derived 
dendritic cells and bone marrow derived macrophages 
Finally, we speculated that focal upregulation of JAM-B expression on CNS infiltrating myeloid cells 
may contribute to immune cell progression across the glia limitans. To this end, we studied if CNS-
infiltrating immune cells are able to upregulate JAM-B and compared this to the potential of BMDCs or 
bone marrow derived macrophages (BMM) to upregulated JAM-B.  To this end, we isolated brain-
infiltrating immune cells and sorted them into CD45hi infiltrating immune cells and CD45lo myeloid cells 
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by flow cytometry. Performing real-time PCR did not allow to detect expression of JAM-B on any of the 
CNS isolated immune cell subsets (Fig. 10 and data not shown). Furthermore, we did not detect 
expression of JAM-B mRNA in LPS-matured BMDC or BMM from wild-type C57BL/6J mice and JAM-
B-/- mice (Fig. 10) while expression of JAM-B was readily detectable in Madin-Darby Canine Kidney 
(MDCK) cells transfected with mouse JAM-B (Fig. 10). These data underscore that in the mouse JAM-
B is not expressed on hematopoietic cells. Thus, trapping of immune cells in perivascular and 
leptomeningeal spaces is not due to a lack of JAM-B/α4β1-integrin mediated interaction of antigen-
presenting cells with autoaggressive T cells.  
 
Taken together, our study shows that if encephalitogenic T cells are primed in vivo lack of JAM-B 
results in the amelioration of EAE due to the fact that inflammatory cells are trapped mainly in the 
leptomeningeal and to a certain degree in perivascular spaces by an unknown mechanism. 
 
 
4 Discussion 
Junctional adhesion molecule B (JAM-B) has been described to localize to vascular endothelial tight 
junctions and to function as a vascular ligand for α4β1-integrin on immune cells (Cunningham et al., 
2002) (Ludwig et al., 2009). Blood-brain barrier (BBB) breakdown and immune cell trafficking into the 
central nervous system are early hallmarks of multiple sclerosis (MS) and its animal model 
experimental autoimmune encephalomyelitis (EAE). In MS and EAE, tight junction architecture 
changes and α4β1-integrins play a prominent role in the migration of auto-aggressive immune cells 
into the CNS during autoimmune neuroinflammation. This prompted us to study the role of the tight 
junction protein JAM-B in the pathogenesis of EAE and MS.  
 
In accordance to previous studies pointing to an endothelial cell specific expression of JAM-B in 
peripheral organs (Boscacci et al., 2010) we here confirm endothelial cell specific expression of JAM-
B in the CNS. While we found no expression of JAM-B in choroid plexus epithelial cells forming the 
BCSFB, JAM-B was detected on BBB forming endothelial cells in the parenchyma and leptomeninges 
but also in endothelial cells of the fenestrated microvessels in the choroid plexus. Endothelial JAM-B 
expression in the CNS thus does not correlate with endothelial barrier characteristics. This is in 
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contrast to other tight junction proteins, e.g. claudin-5, which is highly expressed in plasmalemmal 
vesicle-associated protein (PLVAP)-negative barrier forming endothelial cells, but absent from the 
PLVAP-positive fenestrated microvascular endothelial cells in the choroid plexus (Zhou et al., 2014).  
 
Lack of a role for JAM-B in establishing or maintaining a functional BBB is confirmed by our present 
observation that JAM-B-/- C57BL/6J mice display a functional BBB during health also in ageing and do 
not show any increased diffusion of different sized endogenous and exogenous vascular tracers 
across the BBB during EAE. Our present study shows that maintenance of barrier integrity in the 
absence of JAM-B is not due to the compensatory upregulated expression of other tight junction 
proteins. Thus, at least homophilic interactions of JAM-B are not essential for BBB integrity. In 
addition, heterophilic interactions of JAM-B with JAM-C need to be considered as JAM-B has been 
shown to stabilize JAM-C localization in endothelial tight junctions (Arcangeli et al., 2014). Although 
JAM-C expression in the CNS is not restricted to endothelial cells, its expression at the vascular level 
overlaps with that of JAM-B observed in the present study, namely to barrier forming and non-barrier 
forming CNS vascular endothelium (Wyss et al., 2012). JAM-C-/- C57BL/6J mice develop a 
hydrocephalus which is however not due to the vascular function of JAM-C as endothelial re-
expression of JAM-C fails to rescue the hydrocephalus phenotype of JAM-C-/- mice (Wyss et al., 
2012). Thus, also a potential loss of JAM-C from JAM-B-deficient endothelial junctions will not lead to 
BBB disruption, underscoring that neither homophilic JAM-B/JAM-B nor heterophilic JAM-B/JAM-C 
interactions are essential in establishing BBB integrity.  
 
Next, we considered the role of JAM-B in mediating immune cell entry into the CNS in an α4β1-integrin 
dependent fashion.  Immune cell trafficking across the vascular wall is a multi-step process, in which 
upon its initial interaction with the inner lining of the vessels the immune cell rolls along the 
endothelium allowing it to reduce its velocity and to interact with vascular ligands that in a subsequent 
step trigger the additional activation of immune cell integrins, which leads to the integrin mediated 
immune cell arrest on the endothelium. Following crawling on the endothelial surface, the immune cell 
eventually crosses the endothelial barrier at paracellular or transcellular sites of diapedesis. JAM-B 
has been suggested mediate different steps of T-cell migration across the vascular wall. In vitro and in 
vivo live cell imaging studies demonstrated a role for JAM-B in mediating α4β1-integrin mediated 
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immune cell rolling and arrest to the vascular wall independent of JAM-C (Ludwig et al., 2009). 
Additional studies showed that following interaction with JAM-C, endothelial JAM-B can engage α4β1-
integrin and mediate T-cell diapedesis across the vascular wall (Cunningham et al., 2002).  First 
evidence for a potential role of JAM-B in mediating T-cell trafficking to the CNS was provided in our 
previous study in a CD8 T-cell mediated model of CNS autoimmune inflammation in BALB/c mice, in 
which we found an essential role for α4β1-integrin in mediating CD8+ T cell entry into the CNS (Martin-
Blondel et al., 2015). Injection of function blocking antibodies identified JAM-B in addition to VCAM-1, 
as vascular ligands involved in α4β1-integrin mediated CD8+ T cell migration across the BBB (Martin-
Blondel et al., 2015). More importantly, we observed that blocking of JAM-B rather than VCAM-1 
reduced clinical signs of CD8+ T cell mediated autoimmune neuroinflammation.  
These experimental observations combined with the known prominent role of α4β1-integrins in 
mediating immune cell entry into the CNS in EAE and also MS suggest a potential role for vascular 
JAM-B in the pathogenesis of these diseases. Observing ameliorated EAE in JAM-B-/- C57BL/6J mice 
compared to wild-type littermates thus at a first glance supported the notion of a role of vascular JAM-
B in T-cell migration across the BBB. However, the isolation of significantly higher numbers of immune 
cells from the brains and spinal cords of JAM-B-/- mice when compared to wild-type littermates at the 
peak of the disease contradicted this assumption. We found no difference in the composition of the 
isolated immune cell infiltrates with respect to the presence of immune cell subsets between wild-type 
and JAM-B-/- C57BL/6J mice during the peak of EAE. Furthermore, analyzing the cytokine profile of 
CNS infiltrating T cells showed no difference in the expression of the Th1 and Th17 signature 
cytokines IFN-γ, IL-17 and GM-CSF or the Th2 signature cytokine IL-4. Thus lack of JAM-B does 
neither inhibit nor facilitate the migration of a given immune cell subset across the BBB.  
Employing an in vitro model of the BBB that has previously allowed to define the precise roles of 
endothelial VCAM-1 and ICAM-1 and ICAM-2 in the multi-step T-cell extravasation across the BBB by 
means of live cell imaging (Abadier et al., 2015; Steiner et al., 2010) failed to show any involvement of 
endothelial JAM-B in T-cell migration across the BBB. These in vitro investigations were, however, 
hampered by lower expression levels of JAM-B in brain endothelial cells that despite the detection of 
JAM-B mRNA expression did not allow for detection of JAM-B protein.  
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Taken together, these data suggest that in this CD4+ T cell driven CNS autoimmune disease other 
vascular α4β1-integrin ligands, namely VCAM-1 and fibronectin, rather than JAM-B mediate immune 
cell migration across the BBB (Engelhardt et al., 1998; Man et al., 2009).  
 
To examine how the presence of increased numbers of immune cells in the CNS of JAM-B-/- C57BL/6J 
mice suffering from EAE can be correlated to the ameliorated disease course observed when 
compared to wild-type littermates, we next performed immunostainings of brain and spinal cord 
sections and analyzed the localization of the immune cell infiltrates.  While in the CNS of wild-type 
mice perivascular cuffs and inflammatory cell infiltrates were observed mainly in the spinal cord and 
cerebellum in a pattern typical for EAE in C57BL/6 mice, in the brains and spinal cords of JAM-B-/- 
C57Bl/6J mice the majority of immune cells was found to accumulate within the leptomeninges and in 
some mice also in perivascular spaces leading to a massive enlargement of these compartments. 
Absence of JAM-B was also associated with the leptomeningeal and perivascular accumulation of 
cellular infiltrates in the cerebrum and brain stem, which is not typically seen in EAE in C57BL/6 mice.  
 
Thus, although JAM-B does not impair immune cell migration across the BBB its absence causes 
accumulation of inflammatory cells mainly in the leptomeningeal but also in perivascular spaces 
bordered by the endothelial and parenchymal basement membranes.  Thus also in the absence of 
JAM-B the molecular mechanisms, e.g. interaction of T cell α4β1- and αLβ2-integrins with endothelial 
VCAM-1 and ICAM-1/ ICAM-2 respectively, mediating the initial T-cell migration across 
leptomeningeal vessels as visualized by intravital microscopy (Bartholomaus et al., 2009; Schlager et 
al., 2016; Vajkoczy et al., 2001) and subsequently across the BBB in parenchymal microvessels are 
intact.  
 
Leptomeningeal and perivascular trapping of CNS infiltrating cells in EAE has been observed before in 
L-selectin KO mice (Grewal et al., 2001), macrophage-depleted mice (Tran et al., 1998), in TNF-α KO 
mice (Korner et al., 1997), and in MMP2/MMP9 double KO mice (Agrawal et al., 2006). Lack of the 
respective cell or molecule was found to be involved in the mechanisms mediating immune cell 
migration across the glia limitans underscoring the concept that immune cell migration into the CNS 
requires sequential crossing of two distinct barriers (Owens et al., 2008). Passage across the 
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endothelial BBB is the first step allowing for immune surveillance of the CNS without affecting CNS 
function, while the second step, in which immune cells cross the glia limitans and enter the CNS 
parenchyma correlates with the onset of clinical EAE (Sixt et al., 2001). These previous observations 
have thus provided evidence that the molecular mechanisms involved in immune cell penetration 
across the glia limitans differ from those involved in crossing the endothelial component of the BBB.  
In fact, it has been shown that T cell penetration across the glia limitans in EAE requires re-activation 
of encephalitogenic T cells in the perivascular and leptomeningeal spaces by recognition of their 
cognate antigen on the local antigen-presenting cells (Bartholomaus et al., 2009). Increased 
expression of TNF-α by the antigen-presenting cells triggered by the T-cell interaction induces 
localized induction of astrocyte-derived gelatinases MMP2 and MMP9.  The local activity of these 
gelatinases leads to the cleavage of the astrocyte extracellular matrix receptor β-dystroglycan 
(Agrawal et al., 2006) and modulates the local activity of chemokines at this CNS border (Song et al., 
2015) allowing in a final step immune cell exit from perivascular and leptomeningeal spaces across 
the glia limitans into the CNS parenchyma.  
In a series of experiments we aimed to define a potential role for JAM-B in the above outlined cascade 
of molecular mechanism promoting immune cell migration across the glia limitans in EAE. We 
excluded a potential contribution of upregulation of JAM-B on myeloid cells in CNS leptomeningeal 
and perivascular spaces demonstrating lack of JAM-B expression by this immune cell subset. The 
trafficking phenotype (chemokine receptors, integrins) of T cells isolated from the CNS of JAM-B-/- 
mice and wild-type littermates during the peak of the disease was comparable. Absence of JAM-B 
also did not affect immune cell proliferation in the CNS of mice during the peak of EAE. Furthermore, 
in situ zymographies and immunofluorescence stainings confirmed gelatinase activity in the brains of 
JAM-B-/- C57BL/6J mice during the peak of EAE to be indistinguishable from that observed in their 
wild-type littermates. Thus, the accumulation of immune cells in perivascular and leptomeningeal 
spaces and their inability to exit from these compartments in the absence of JAM-B is not due to 
alterations in the T-cell characteristics or their local reactivation. 
 
We next hypothesized that lack of JAM-B may affect BBB polarity and subsequent loss of chemokine 
gradients required for immune cell entry into the CNS parenchyma during EAE.  High concentrations 
of the chemokine CXCL12 have been suggested to maintain localization of CXCR4 expressing 
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effector/memory T cells in perivascular and leptomeningeal spaces during CNS immunosurveillance 
(McCandless et al., 2006). During EAE expression of the CXCL12 scavenging receptor 
CXCR7/ACKR3 is increased leading to internalization and inactivation of CXCL12 (Cruz-Orengo et al., 
2011). Reducing the levels of CXCL12 have been correlated with increased migration of infammatory 
cells across the glia limitans probably due to facilitated migration towards gradients of inflammatory 
chemokines produced by astrocytes (summarized in (Huang et al., 2000)).  Based on these previous 
observations we investigated localization of CXCL12 by immunofluorescent stainings on brain tissues 
from wild-type and JAM-B-/- mice. Although we could confirm loss of perivascular staining for CXCL12 
in mice suffering from EAE we did not detect any difference in CXCL12 immunostaining in wild-type 
and JAM-B-/- mice. In accordance to these findings we also did not find any loss of BBB polarity based 
on immunostaining for Glut-1 and Pgp in mice lacking JAM-B. Taken together these data exclude a 
role of altered chemokine gradients responsible for immune cell accumulation in CNS leptomeningeal 
and perivascular spaces in JAM-B-/- mice during EAE.   
 
Increased numbers of immune cells in perivascular and leptomeningeal compartments could 
theoretically also be due to an increased immigration of circulating immune cells across the BBB. 
Indeed, it is known that besides VCAM-1 and CXCL12, also JAM-B expressed by bone marrow 
stromal cells contributes to the maintenance of the hematopoietic stem cell niche (Arcangeli et al., 
2011). We therefore also addressed, if JAM-B-/- C57BL/6J mice release an increased number of 
(immature) bone marrow derived cells into the blood stream following an inflammatory stimulus.  
Analysis of the bone marrow and the blood of wild-type and JAM-B-/- mice did not provide any 
evidence for increased release of bone marrow derived cells into the blood stream in response to the 
massive CFA stimulus employed to induce EAE as a potential increased source of immune cells 
crossing the BBB of JAM-B deficient mice during EAE.  
 
Finally, we considered a potential role of JAM-B in the activation of encephalitogenic T cells in 
peripheral immune organs after induction of EAE by immunization with the MOG35-55 peptide in CFA. 
JAM-B is expressed in lymphatic and vascular endothelial cells of peripheral lymph nodes (Pfeiffer et 
al., 2008) allowing for its potential involvement in α4β1-integrin mediated T-cell priming. Indeed, α4β1-
integrins have been proposed to be involved in the activation of T cells (Engelhardt et al., 1998). To 
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circumvent in vivo priming of encephalitogenic T cells and to focus on the effector phase of EAE, we 
therefore studied EAE pathogenesis upon transfer of in vitro antingen-activated encephalitogenic T 
cells derived from wild-type or JAM-B-/- C57BL/6J mice into either wild-type or JAM-B-/- C57BL/6J 
mice. We did not observe any difference in disease development in any of the recipient mice, 
irrespective of the absence or presence of JAM-B that could have supported a role of JAM-B in T cell 
priming in the peripheral immune system. Furthermore, at the same time in vitro antigen -activated T 
cells derived from JAM-B-/- mice did not show any impairment in transferring EAE when compared to 
antigen -activated T cells derived from wild-type mice. Interestingly, we did not observe accumulation 
of inflammatory cells in leptomeningeal and perivascular spaces in transfer EAE underscoring that 
JAM-B is not required for focal reactivation of T cells prior to their migration across the glia limitans.  
It has been reported that α4β1-integrins are recruited to the immunological synapse, where they can 
control T-cell priming and proliferation suggesting a potential role for α4β1-integrin ligands including 
JAM-B in this process (Mittelbrunn et al., 2004). Although we did not detect expression of JAM-B in 
hematopoietic cells in the mouse, we confirmed that lack of JAM-B does not affect availability of 
antigen-presenting cells in peripheral lymph nodes and verified that JAM-B is not required for in vivo 
activation of MOGaa35-55 –specific encephalitogenic T cells.  The comparable T-cell cytokine profiles for 
IFN-γ, IL-17, GM-CSF and IL-4 in T cell subsets from wild-type and JAM-B-/- mice corroborated the 
notion that JAM-B does not play a critical role in in vivo priming, proliferation or polarization of 
encephalitogenic CD4+ T cells in peripheral immune organs.  This is in accordance with our previous 
observations that lack of β1-integrins on encephalitogenic T cells and thus of the JAM-B ligand α4β1-
integrin, does not affect their priming and proliferation (Bauer et al., 2009).  
 
5 Conclusion 
Taken together, our data demonstrate that JAM-B is neither required for peripheral T-cell activation 
nor for immune cell trafficking across the BBB in EAE. Rather, its absence causes the trapping of 
inflammatory cells mainly in CNS leptomeningeal and to a lesser degree in perivascular spaces and 
thus amelioration of EAE by mechanisms distinct from those described to date that have lead to 
similar phenotypes. Further studies will have to address, if endothelial JAM-B could play a role in 
triggering integrin activation of immune cells crossing the BBB as previously described for PECAM-1 
in regulating the activation of neutrophil integrins during endothelial diapedesis in peripheral tissues 
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(Dangerfield et al., 2002). In this context absence of PECAM-1 was found to lead to the trapping of 
neutrophils in the vascular basement membranes due to their failure to activate α6β1-integrins, which 
is required for neutrophils to cross the basement membrane. In the present context, α4β1-mediated 
interaction of T cells with vascular JAM-B may contribute to the subsequent activation of α6β1-
integrins required to engage the parenchymal basement membrane of the glia limitans and thus 
facilitate exit of the perivascular space.  
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Figure legends 
Figure 1: Co-localization of JAM-B and PECAM-1 in the CNS of C57BL/6J mice 
Immunoﬂuorescence staining for JAM-B in the mouse CNS was evaluated on 6 µm cryosections of 
brains and spinal cord of healthy wild-type (WT) C57BL/6J mice. Immunoﬂuorescence staining for 
JAM-B (third vertical row, red) and PECAM-1 (second vertical row, green) show co-localization of 
JAM-B and PECAM-1 (fourth vertical row, merged) on all vessels in the mouse cortex (first horizontal 
row), the choroid plexus endothelium (second horizontal row), all vessels in the cerebellum (third 
horizontal row), and all vessels in the spinal cord (fourth horizontal row). All sections were counter-
stained with DAPI to show cell nuclei (first vertical row). Bars are 50 µm. Panel shown above 
constitutes one representative staining; in total three individual tissues were processed. For all 
pictures shown in the panel above Brightness and contrast were adjusted (brightness 72; contrast 
100) using Photoshop CS6 software. 
 
Figure 2: JAM-B-/- C57BL/6J mice develop ameliorated EAE.  
A: The clinical severity of MOG35-55 induced EAE as followed over 35 days in wild-type (WT; black 
dots) and JAM-B-/- C57BL/6J mice (grey squares) is shown. B: Overall disease severity as determined 
by the area under the curve (AUC) and analyzed until day 35 showed a significant reduction in JAM-B-
/- mice (median 11) when compared to wild-type (WT) littermates (median 17.25). Bar graphs 
represent the mean ± SEM of 3 independent experiments including n = 22 WT and n = 20 JAM-B-/- 
mice. Statistical analysis was performed using the GraphPad Prism 6 software. Differences in 
between the AUCs were evaluated by Man-Whitney test p > 0.01**. C: Body weight of wild-type (WT; 
black dots) and JAM-B-/- littermates (grey squares) during EAE progression is shown; mean ± SEM. D: 
The maximal clinical score was evaluated as mean of the maximal score of each mouse (n = 22 wild-
type (WT), black bar; n = 20 JAM-B -/- mice, grey bar) during the disease progression. The mean 
maximal clinical score of WT mice was 1.5 ± 0.13 and mean maximal score of JAM-B-/- mice 1 ± 0.09. 
Differences between the maximal clinical score are evaluated by student’s t-test; p values > 0.01**. 
 
Figure 3: In vivo BBB permeability in C57BL/6J wild-type and JAM-B-/- mice suffering from EAE 
A: Representative pictures show 3 kDa Dextran (red) and 10 kDa Dextran (green) in the choroid 
plexus (3rd ventricle) in the brain of wild-type (WT; upper row; EAE day 18 score 2) and JAM-B-/- 
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C57BL/6J mice (lower row; EAE day 18 score 2) suffering from EAE. B: Representative pictures show 
3 kDa Dextran (red) and 10 kDa Dextran (green) in blood vessels in the cortex in the brain of wild-type 
(WT; upper row) and JAM-B-/- mice (lower row) suffering from EAE. C: Representative pictures show 3 
kDa Dextran (red) and 10 kDa Dextran (green) in the cerebellum of WT (upper row) and JAM-B-/- mice 
(lower row) suffering from EAE. 3 kDa Dextran and 10 kDa Dextran is present in the perivascular 
space of inflammatory cuffs (white arrowheads) WT (upper row) and JAM-B-/- mice (lower row) 
suffering from EAE. Scale bars = 50 µm. In total three individual tissues per genotype were processed 
(EAE day 18; n = 3 WT scores: n = 2 score 2, n = 1 score 1; n = 3 JAM-B-/- C57BL/6J scores: n = 1 
score 2, n = 2 score 1).  
 
Figure 4: Increased numbers of CD45+ inflammatory cells infiltrate the CNS of JAM-B-/- 
C57BL/6J mice when compared to WT littermates at the peak of EAE 
A: Exemplary demonstration of the gating strategy of CD45+ immune cells isolated from the spinal 
cords of n = 4 wild-type (WT) at the peak of EAE (day 16 or day 20 post EAE-induction) is shown. A 
gate was set to the CD45hiSSClo population (left graph), which was further gate on CD3 and CD4 
(middle graph). Four rectangular gates were set according to the isotype control (right graph) to divide 
non-overlapping populations using the FlowJo software version 10. WT allocated gates were pasted to 
the data obtained from JAM-B-/- C57BL/6J mice. B: Bar graphs show the mean ± SD percentage of 
CD45hiSSClo infiltrating immune cell populations isolated from the brains of n = 12 wild-type (WT) mice 
(black bars) and n = 12 JAM-B-/- mice (grey bars) at the peak of EAE. Data are plotted as a summary 
of 3 independent experiments including n = 4 mice (pooled) per genotype and experiment. C: Bar 
graphs show the mean ± SD percentage of CD45hiSSClo infiltrating immune cell populations isolated 
from the spinal cords of n = 12 wild-type (WT) mice (black bars) and n = 12 JAM-B-/- mice (grey bars) 
at the peak of EAE. Data are plotted as a summary of 3 independent experiments including n = 4 mice 
(pooled) per genotype and experiment. D: Absolute numbers of CD45hiSSClo brain infiltrating immune 
cell subsets per mouse were levied by projection to the number of flow cytometry counting beads. 
Data show the number of brain infiltrating CD45hiSSClo cells of n = 12 JAM-B-/- mice (grey bars) 
normalized to n = 12 wild-type (WT) mice (black bars); mean ± SD. Data are plotted as a summary of 
3 independent experiments including n = 4 mice (pooled) per genotype and experiment. For statistical 
analysis the student’s t-test was used to determine differences between the groups and p values > 0.5 
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were assigned to be significant*. E: Absolute numbers of CD45hiSSClo brain infiltrating immune cell 
subsets per mouse were levied by projection to the number of flow cytometry counting beads. Data 
show the number of brain infiltrating CD45hiSSClo cells of n = 12 JAM-B-/- mice (grey bars) normalized 
to n = 12 wild-type (WT) mice (black bars); mean ± SD. Data are plotted as a summary of 3 
independent experiments including n = 4 mice (pooled) per genotype and experiment. For statistical 
analysis the student’s t-test was used to determine differences between the groups and p values > 0.5 
were assigned to be significant*. 
  
Figure 5: CD45+ inflammatory cells are trapped in leptomeningeal and perivascular spaces in 
the CNS of JAM-B-/- C57BL/6J mice at the peak of EAE.   
To investigate the localization of CNS infiltrating CD45+ immune cells in WT and JAM-B-/- C57BL/6J 
mice at the peak of EAE, immunofluorescence staining was performed on 6 µm cryosections of brain 
and spinal cord tissue. Representative pictures from the cerebrum, brain stem and the spinal cord of 
wild-type (WT) mice and JAM-B-/- mice with clinical EAE (day 16, clinical score 2) are shown.  Three 
mice per genotype were analyzed at the peak of EAE (day 16 after immunization; n = 2 WT and n = 2 
JAM-B-/- mice score 2 and n = 1 WT and n = 1 JAM-B-/- mice score 1). Trapping of CD45+ immune 
cells (red) between the endothelial and parenchymal basement membranes (laminin staining in green) 
and thus widening of these spaces is obvious in tissue sections of JAM-B-/- mice when compared to 
WT littermates. Blue = nuclear staining with DAPI. Scale bar 100 µm. Representative pictures from the 
cerebrum show the periventricular space adjacent to the choroid plexus (3rd ventricle). Pictures from 
the brain stem show trapped immune cells in the leptomeninges. Selected pictures from the spinal 
cord show meningeal infiltration in the lumbar spinal cord as well as inflammatory cuffs in the white 
matter. 
 
Figure 6: Analysis of gelatinase (MMP) activity in EAE brains by in situ zymography  
In situ zymography coupled with pan-laminin (blue) and CD45 (red) immunofluorescence staining on 
brain sections of wild-type (WT) and JAM-B-/- C57BL/6J mice with EAE (day 16; n = 2 WT, score 2 and 
score 1; n = 2 JAM-B-/-, score 2 and score 1) is shown.  Proteolytic digestion of DQ-gelatine 
unquenches the bright green fluorescence of fluorescein, which allows to localize gelatinase/MMP 
activity. While patchy areas of green fluorescence on the tissue section have to be considered as 
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unspecific signal, local MMP activity is observed by the typical granular bright green fluorescence 
signal, examples of which are highlighted by the arrowheads. Specific MMP activity can therefore be 
visualized in the cerebellum beyond the parenchymal basement membrane (blue) at parenchymal and 
leptomeningeal sites of immune cell infiltration (red). Note the large Scale bar = 100 µm. 
Representative pictures of a total of 3 mice per genotype analyzed. Pictures were taken how and. 
Brightness and contrast were adjusted (brightness 72; contrast 100) using Photoshop CS6 software. 
 
Figure 7: Analysis of blood of CFA challenged mice  
Evaluation for the number of leukocytes (white blood cells) in the blood of CFA immunized C57BL/6J 
wild-type (WT; black dots, n = 9) and JAM-B-/- mice (grey dots, n = 9) at days 2, 4, and 10 after CFA 
challenge (left column). Second column: numbers of lymphocytes at days 2, 4, and 10 after CFA 
challenge of WT (black dots, n = 9) and JAM-B-/- mice (grey dots, n = 9). Third column: numbers of 
monocytes at days 2, 4, and 10 after CFA challenge of WT (black dots, n = 9) and JAM-B-/- mice (grey 
dots, n = 9). Right column: numbers of granulocytes at days 2, 4, and 10 after CFA challenge of WT 
(black dots, n = 9) and JAM-B-/- mice (grey dots, n = 9). Data are displayed as a summary of three 
independent experiments including 3 mice per genotype; each dot represents 1 mouse 
 
Figure 8: Adoptive transfer EAE induced by polyclonal encephalitogenic CD4+ T cell transfer in 
C57BL/6J wild-type and JAM-B-/- mice  
Clinical course of adoptively transferred EAE by intraperitoneal injection of 2.5 x 106 MOGaa35-55-
activated CD4+ T cells obtained from wild-type (WT) donor mice into WT recipients (black dots; WT  
WT)  and JAM-B-/- littermates (grey dots; WT  JAM-B-/-) and clinical course of adoptively transferred 
EAE by intraperitoneal injection of 2.5 x 106 MOGaa35-55-activated CD4+ T cells obtained from JAM-B-/- 
donor mice into WT (black squares; JAM-B-/-  WT) and JAM-B-/- mice (grey squares; JAM-B-/-  
JAM-B-/-).  Adoptive transfer EAE was followed over 29 days in a total of n = 19 WT and n = 19 JAM-B-
/- mice. Data show mean ± SEM as a summary of three independent experiments including n = 5-7 
mice per group, respectively. Overall disease severity is shown as area under the curve (AUC) for WT 
 WT tEAE (black bars), WT  JAM-B-/- mice (grey bars black cross-striped), JAM-B-/-  WT (black 
bars grey cross-striped), and JAM-B-/-  JAM-B-/-).  (grey bars); mean ± SEM. Statistical analysis was 
performed using the GraphPad Prism 6 software; one-way ANOVA; p = 0.6406.  
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Figure 9: In vitro proliferation of MOG35-55 T-cell receptor transgenic 2D2 T cells in response to 
MOG35-55 peptide presented by bone marrow derived dendritic cells  
A: The graph shows the CPMA values of proliferating naïve 2D2 T cells co-cultured with either 
BMDCs generated from wild-type (WT, black dots) C57BL/6J mice or JAM-B-/- littermates (grey 
squares) in the medium control, tuberculin purified protein derivative (PPD) negative control, and anti-
CD3/anti-CD28 positive control. B: The graph shows increasing CPMA levels correlating to increasing 
concentrations of MOG in both naïve 2D2 T cells co-cultured with BMDCs generated from wild-type 
(WT, black dots) C57BL/6J mice and JAM-B-/- littermates (grey squares). The data show 1 experiment 
as a representative of 3 independent experiments; mean ± SD. All concentrations were set up as 
triplicates in each experiment.  
 
Figure 10: JAM-B expression on BMDC, BMM, and brain-infiltrating immune cells 
The graph shows JAM-B ΔCt values (ΔCt(GOI) = Ct(GOI)-Ct(s16 normalizer)). MDCK Fc-JAM-B (n = 
1) positive control; black bar. JAM-B ΔCt values of BMDCs (bright grey bars) as well as JAM-B ΔCt 
values of BMMs (dark grey bars) from wild-type (WT) and JAM-B-/- C57BL/6J mice are presented as 
mean ± SD from three independent preparations including 1 mouse per genotype. JAM-B ΔCt form 
pooled brain-infiltrating CD45hi cells obtained from C57BL/6J mice (n = 9: score 2 n = 6 and score 1 n 
= 3) at day 16 after EAE induction (blue bar). 
 
